Selective serotonin reuptake inhibitors in human pregnancy: On the way to resolving the controversy

Keyphrases

• Human Pregnancy 100%
• Selective Serotonin Reuptake Inhibitors 100%
• Developmental Issues 28%
• Untreated Depression 28%
• Developmental Follow-up 28%
• Preterm Delivery 14%
• Neonate 14%
• During Pregnancy 14%
• Ascertainment Bias 14%
• Maternal Depression 14%
• Major Anomalies 14%
• Developmental Disorders 14%
• Major Malformations 14%
• Postpartum Depression 14%
• Absolute Risk 14%
• Child Development 14%
• Cardiovascular Malformations 14%
• Appropriate Treatment 14%
• Treatment during Pregnancy 14%
• Overall Risk 14%
• Treatment Discontinuation 14%
• Poor Neonatal Adaptation 14%
• Persistent Pulmonary Hypertension of the Newborn 14%
• Neurobehavioral Problems 14%
• Cardiovascular Anomalies 14%
• Inhibitor Treatment 14%
• Risk-benefit Analysis 14%
• Risk-benefit Ratio 14%
• Minimal Effective Dose 14%
• Cohort Data 14%

Medicine and Dentistry

• Selective Serotonin Reuptake Inhibitor 100%
• Postpartum Depression 28%
• Cardiovascular Malformation 28%
• Congenital Malformation 14%
• Child 14%
• Neonatal Infant 14%
• Developmental Disorder 14%
• Premature Labor 14%
• Child Development 14%
• Neonate 14%
• Risk-Benefit Ratio 14%
• Risk Benefit Analysis 14%
• Ascertainment Bias 14%
• Persistent Fetal Circulation 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Selective Serotonin Reuptake Inhibitor 100%
• Postnatal Depression 28%
• Cardiovascular Malformation 28%
• Congenital Malformation 14%
• Premature Labor 14%
• Developmental Disorder 14%
• Persistent Pulmonary Hypertension 14%